Eli Lilly (LLY) EPS (Weighted Average and Diluted) Growth (3y) (2015 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
76.98% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
318.57% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
44.22% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-52.54% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-14.16% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
26.25% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-21.46% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
6.98% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
76.98% |
| Dec 31, 2025 |
51.15% |
| Sep 30, 2025 |
56.83% |
| Jun 30, 2025 |
81.62% |
| Mar 31, 2025 |
13.37% |
| Dec 31, 2024 |
37.19% |
| Sep 30, 2024 |
-4.28% |
| Jun 30, 2024 |
28.94% |
| Mar 31, 2024 |
18.51% |
| Dec 31, 2023 |
1.42% |
| Sep 30, 2023 |
-26.93% |
| Jun 30, 2023 |
7.95% |
| Mar 31, 2023 |
-2.35% |
| Dec 31, 2022 |
9.28% |
| Sep 30, 2022 |
5.53% |
| Jun 30, 2022 |
-9.99% |
| Mar 31, 2022 |
54.45% |
| Dec 31, 2021 |
19.77% |
| Sep 30, 2021 |
4.47% |
| Jun 30, 2021 |
107.66% |
| Mar 31, 2021 |
8.70% |
| Dec 31, 2020 |
51.37% |
| Sep 30, 2020 |
35.89% |
| Jun 30, 2020 |
17.73% |
| Mar 31, 2020 |
162.07% |
| Dec 31, 2019 |
30.97% |
| Sep 30, 2019 |
23.35% |
| Jun 30, 2019 |
26.58% |
| Mar 31, 2019 |
11.61% |
| Dec 31, 2018 |
34.71% |
| Sep 30, 2018 |
12.57% |
| Jun 30, 2018 |
-33.75% |
| Mar 31, 2018 |
32.38% |
| Dec 31, 2017 |
-81.21% |
| Sep 30, 2017 |
4.09% |
| Jun 30, 2017 |
11.79% |
| Mar 31, 2017 |
-29.01% |
| Dec 31, 2016 |
2.90% |
| Sep 30, 2016 |
-13.04% |
| Jun 30, 2016 |
-13.84% |
| Mar 31, 2016 |
-33.91% |
| Dec 31, 2015 |
-15.28% |
| Sep 30, 2015 |
-14.02% |
| Jun 30, 2015 |
-12.29% |
| Mar 31, 2015 |
-18.10% |